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a  b  s  t  r  a  c  t
From  the MDI-liraglutide  study,  we  evaluated  variables  associated  with  endogenous  insulin  production
in  persons  with  multiple  daily  insulin  injections-treated  type  2 diabetes  by relating  C-peptide,  proinsulin
and  proinsulin/C-peptide  ratio  at  baseline  to baseline  variables.  Lower  insulin  production  was  related  to
longer  diabetes  duration,  shorter  abdominal  sagittal  diameter  and more  glycaemic  variability.
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Type 2 diabetes (T2D) is a progressive disease with decreased
insulin secretion in the later stages [1]. There are several treatment
options to achieve good glycaemic control in these patients [2].
As a final step, when glycaemic control still does not meet target
levels, multiple daily insulin injections (MDI) with basal and pran-
dial insulin have been standard care approaches [3]. Endogenous
insulin production exists for most persons in this population [4].
Insulin secretion is commonly measured by C-peptide [5], and the
proinsulin/C-peptide ratio is used as a measurement of beta-cell
dysfunction [6]. C-peptide levels have been associated with degree
of diabetes complications and may  have a biological importance
[7–9].
Reduced endogenous insulin production likely leads to more
fluctuating glucose levels and need of support with glucose-
∗ Corresponding author at: Department of Medicine, NU-Hospital Group, Troll-
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ontinuous glucose monitoring (CGM). Defining risk factors for
educed insulin secretion will increase the possibility for clinicians
o identify patients in need of extra support. To our knowledge,
here is a lack of contemporary studies of variables associated with
ow endogenous insulin secretion in persons with T2D treated with
DI. Additionally, studies investigating the association between
nsulin production and glycaemic variability using CGM data are
carce.
The aim of the current study was  to increase the understanding
f variables related to endogenous insulin production in persons
ith T2D treated with MDI.
. Methods
The MDI-liraglutide study was  approved by the Ethics Commit-
ee of the University of Gothenburg, Gothenburg, Sweden (13thf November, 2012, diary number 596-12). The design and meth-
ds for the above-mentioned study has been described in detail
lsewhere [4,10]. Briefly, it was  a randomised, placebo-controlled,
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in Sweden. All participants granted written informed consent to
participate.
2.1. Screening
The main inclusion criteria were persons clinically diagnosed
with T2D and treated with MDI, HbA1c concentrations ≥58
mmol/mol (7.5%) and ≤102 mmol/mol (11.5%), and fasting serum
C-peptide level ≥ 0.1 nmol/L.
2.2. Run-in period and baseline characteristics
After a run-in period of maximum eight weeks, with masked
CGM (DexCom G4 PLATINUM, San Diego, CA) use for one week,
baseline characteristics were measured. Serum C-peptide and
proinsulin were measured in fasting condition and analysed at a
central laboratory located at Karolinska University Hospital, Stock-
holm, Sweden.
2.3. Endpoints
In this study we evaluated C-peptide, proinsulin and
proinsulin/C-peptide levels at baseline related to different
baseline variables; fasting plasma glucose (FPG), age, sex, smoking,
metformin use, glutamic acid decarboxylase (GAD) antibodies,
diabetes duration, height, weight, BMI, abdominal sagittal diame-
ter, hip circumference, waist circumference, waist/hip ratio, total
daily basal insulin dose, total daily meal and basal insulin dose,
HbA1c, CGM (mean and standard deviation (SD)), CGM coefficient
of variation (CV), mean amplitude of glycaemic excursions (MAGE),
systolic and diastolic blood pressure, and serum adiponectin levels.
Subsequently, in an additional analysis, all variables were adjusted
for the corresponding FPG level.
2.4. Statistics
Statistical analyses were performed using linear regression with
the logarithm of C-peptide, proinsulin or proinsulin/C-peptide ratio
as response variable, and the baseline variables described above as
explanatory variables. The baseline variables were analysed one
at a time in univariable (unadjusted) analyses and thereafter also
adjusted for fasting plasma glucose by adding to the model fasting
plasma glucose as a second explanatory variable. Exponentiated
regression coefficients are presented with 95% confidence intervals
(CI), estimating the expected multiplicative change in C-peptide,
proinsulin or proinsulin/C-peptide ratio per unit change in the
explanatory variable. P-values ≤ 0.05 were considered statistically
significant.




There were 124 participants randomised between February
2013 and February 2014, of whom 118 had information of C-
peptide levels and 119 had information of proinsulin levels for
being included in the current analyses.
3.2. Baseline variables in relation to C-peptide and proinsulinLower C-peptide levels were associated with longer diabetes
duration (p = 0.028), elevated GAD antibody levels (p = 0.028),
shorter abdominal sagittal diameter (p = 0.013), shorter hip cir-
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reater glycaemic variability estimated by the SD with masked
GM (p < 0.0001), higher glycaemic variability measured by CV and
AGE (p < 0.0001), lower FPG (p < 0.0001), higher systolic blood
ressure (p = 0.039) and having never smoked (p = 0.011). The rela-
ion between C-peptide levels and diabetes duration, abdominal
agittal diameter, CGM SD and FPG is illustrated in Fig. 1. Lower
roinsulin levels were associated with longer diabetes duration (p
 0.011), shorter abdominal sagittal diameter (p = 0.013), lower
ean glucose level estimated by masked CGM (p = 0.046), greater
lycaemic variability estimated by the SD with masked CGM (p =
0.0001), greater glycaemic variability measured by CV and MAGE
p < 0.0001 and p = 0.001, respectively), lower FPG (p < 0.0001) and
aving never smoked (p = 0.007). Lower proinsulin/C-peptide ratio
evels were associated with older age (p = 0.001), longer diabetes
uration (p = 0.019), lower HbA1c (p = 0.037), lower CGM  mean
lucose (p < 0.001), greater glycaemic variability measured by CV
p < 0.001), lower FPG (p = 0.05), lower diastolic blood pressure (p
 0.001), and having never smoked (p = 0.033). Further results are
resented in Table 1, along with all variables being related to C-
eptide, proinsulin, and proinsulin/C-peptide ratio after adjusting
or fasting plasma glucose.
. Discussion
In this study of persons with T2D treated with MDI, lower insulin
roduction estimated by C-peptide, proinsulin and proinsulin/C-
eptide ratio were associated with older age, elevated GAD
ntibody levels, longer diabetes duration, lower FPG, shorter
bdominal sagittal diameter, smaller waist and hip circumference,
reater glycaemic variability, lower glycaemic levels, lower systolic
nd diastolic blood pressure, and having never smoked.
Our findings are in line with previous research that depict higher
-peptide levels in persons with T2D with metabolic syndrome and
igher BMI  [7,9]. However, to our knowledge, there has not been
ny research on persons with type 2 diabetes treated with MDI  as
 subgroup, and furthermore it has not included CGM data.
The results in this study indicate that longer diabetes duration,
horter abdominal sagittal diameter and more glycaemic variability
enerally is associated with lower insulin production, both with-
ut and after adjusting for fasting plasma glucose. Reduced insulin
roduction may  lead to an increase in glucose fluctuations and
herefore these patients are in greater need of glucose-stabilising
reatments in clinical practise.
Whether persons with T2D should get support with more
dvanced glucose monitoring such as traditional continuous glu-
ose monitor or Flash glucose monitor (FGM) is debated. Two
ajor randomised trials on continuous glucose monitor/FGM in
ersons with T2D have shown inconsistent results: in the DIA-
OND study HbA1c improved with 0.3% in the continuous glucose
onitor group but hypoglycaemia incidence did not show any sta-
istical significance, meanwhile Haak et al showed no difference in
bA1c but reduced time in hypoglycaemia with approximately 43%
ith glucose sensing technology [11,12]. Our results indicate that
egree of own  insulin production is likely one of the most essen-
ial factors to determine whether continuous glucose monitor/FGM
s needed as treatment for persons with T2D. These monitors can
uide the patient and health care professionals to take actions to
void excessive glucose fluctuations.
The current study indicates that both future trials and clinical
ractice should look at subgroups regarding need of continuous
lucose monitor/FGM for glucose-stabilising effects and consider
he level of endogenous insulin production. The strengths of the
urrent study are the prospective design with data retrieved from
 placebo controlled randomised clinical trial. The measurements


















C-peptide and proinsulin values in relation to baseline characteristics variables in persons with type 2 diabetes treated with multiple daily insulin injections.
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p < .0001 p < .0001 p = 0.05
n=122












(beta  per 10 years) 65.6 (38.9;
78.0)
p = 0.34 p = 0.20 p = 0.20 p = 0.25 p = 0.001 p = 0.001
n=122













p  = 0.17 p = 0.28 p = 0.49 p = 0.71 p = 0.31 p = 0.23
Smoker  (former or
current)













p  = 0.011 p = 0.07 p = 0.007 p = 0.047 p = 0.033 p = 0.07













p  = 0.73 p = 0.68 p = 0.68 p = 0.66 p = 0.95 p = 0.94













p  = 0.028 p = 0.023 p = 0.17 p = 0.20 p = 0.76 p = 0.80












(beta  per 10 years) 16.0 (2.0;
40.0)
p = 0.028 p = 0.005 p = 0.011 p = 0.003 p = 0.019 p = 0.013
n=122














(beta  per 10 cm)  173.0
(145.0;
194.0)
p = 0.37 p = 0.50 p = 0.98 p = 0.76 p = 0.19 p = 0.14
n=122
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(beta  per 10 cm)  110.5
(94.0;
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(beta  per 10 cm)  114.7
(95.0;
144.8)
p = 0.040 p = 0.041 p = 0.07 p = 0.10 p = 0.28 p = 0.32
n=118












(beta  per 0.1 units) 1.0 (0.8;
1.2)
p = 0.96 p = 0.70 p = 0.63 p = 0.37 p = 0.20 p = 0.15
n=117
Daily  basal insulin
dose (units)












(beta  per 10 units) 56.0 (12.0;
130.0)
p = 0.60 p = 0.73 p = 0.65 p = 0.54 p = 0.19 p = 0.15
n=122
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p = 0.91 p = 0.019 p = 0.046 p = 0.92 p < .001 p = 0.003
n=119
CGM  SD (mmol/L)
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(beta  per 0.1 units) 0.27 (0.16;
0.45)
p < .0001 p < .0001 p < .0001 p < .0001 p < .001 p = 0.005
n=119
MAGE  (mmol/L)


























































p = 0.039 p = 0.010 p = 0.15 p = 0.08 p = 0.97 p = 0.96
Adiponectin (mg/L)














p = 0.23 p = 0.25 p = 0.18 p = 0.21 p = 0.68 p = 0.72
n=121
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Fig. 1. Fasting C-peptide vs. diabetes duration (A), abdominal sagittal diameter (B), C
using  log-linear regression. The shaded region shows 95% pointwise confidence lim
correlation coefficient with log(C-peptide).
and were both included in analyses regarding insulin secretion. A
limitation of the study was the cross-sectional design. Also, mea-
surement of insulin production can be made in a more accurate way
using a glucose clamp or measuring C-peptide after a stimulation
test.
In conclusion, persons with T2D treated with MDI  with longer
diabetes duration, shorter abdominal sagittal diameter and greater
glycaemic variability have reduced insulin production and need
extra focus for glucose-stabilising treatments.
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